BioLargo (BLGO) investor relations material

Strategic vision and business model

• Focuses on transformative, best-in-class technologies in sustainability, health, and engineering, aiming for market leadership in each segment.

• Operates as an incubator and investor, developing assets through adoption cycles and monetizing via joint ventures, IPOs, or sales.

• Maintains a diversified portfolio with low corporate overhead and a capital-conserving approach, leveraging co-investment and partnerships.

• Prioritizes de-risking assets before scaling, with a strong emphasis on finding and responding to market demand.

• Claims unmatched technology in each field, only pursuing opportunities where it can be number one globally.

Portfolio highlights and monetization

• Battery technology targets grid-scale, long-duration storage for AI and data centers, with a strategy to sell factories rather than batteries; four MOUs for 13 factories, each valued at $170 million.

• Clyra Medical, focused on infection control and wound care, has $25 million invested and is entering the adoption phase with global and domestic partners; regulatory approvals in place and manufacturing scaled.

• PFAS technology for eliminating forever chemicals is in its first installation, with a pipeline of over $200 million in projects and partnerships for global deployment.

• Odor and VOC asset, previously the most profitable, experienced a setback due to a lawsuit but is expected to reposition and regain value.

Financial position and valuation

• Current market cap is around $50 million, with an argument for a $200 million valuation based on asset value and monetization potential.

• Holds approximately $4 million in cash, no toxic debt, and a stable, low-burn operational model.

• Portfolio includes assets with significant ROI potential, such as Clyra Medical (49% ownership and 6% royalty) and PFAS (100% ownership), both expected to drive substantial future value.